A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion.

Trial Profile

A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Retinal disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms MIVI-TRUST (TG-MV-007)
  • Sponsors ThromboGenics
  • Most Recent Events

    • 01 Dec 2017 Results of post hoc analysis of two trial (NCT00781859 and NCT00798317) assessing effect of an intravitreal ocriplasmin injection on visual function, measured using visual acuity (VA) and vision-related quality of life, were published in the Acta Ophthalmologica.
    • 01 Jul 2015 Results: pooled analysis, phase III studies published in the American Journal of Ophthalmology.
    • 04 Jun 2014 Pooled analysis ( MIVI -TRUST) results presented at the 19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top